Join us Sept. 14-16 in Miami to connect with top publishing leaders
Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
Future of Marketing Briefing: The public ad tech era is over
Gone are the days when investors got themselves in a tizzy over ad networks, demand-side platforms and supply-side platforms on their own merits.
By the numbers: Wall Street’s tough assessment of ad tech
Big Tech continues to dominate digital growth, triggering a Wall Street exodus, but are returns imminent?
CMOs are struggling to link AI visibility with sales
Brands are spending on tools that rate their visibility within LLM responses and AI search, but proving the commercial impact of GEO remedies isn’t easy.